Who profits from Obamacare..Guess! The Secret Power Elite
The Phamaceutical Companies Big List of Drug Induced Killers
As WND has reported, Charleston church shooter Dylann Roof was a known drug user who was caught with the powerful mind-altering narcotic Suboxone when apprehended by police during an incident on Feb. 28. Suboxone is used to treat addiction to opioid drugs such as heroin. It’s adverse effects include anxiety, irritability, depersonalization, confusion, suicidal thoughts and irrational, sometimes violent behavior.
Other drugs linked to mass killers have more often been geared toward treating mental illness. According to a data set of U.S. mass shootings from 1982-2012 prepared by Mother Jones magazine, of 62 mass shootings carried out by 64 shooters, the majority of the shooters (41) were noted to have signs of possible mental illness — the precise kinds of mental illnesses that psychotropic medications are prescribed for...MORE
Obamacare Illustrated..A picture is worth a thousand words, and, Lord knows, we’ve written thousands – actually, hundreds of thousands – of words about ObamaCare. So on this third anniversary of the passage of this destructive law, we have put together links to resources to help explain the bureaucratic scale of ObamaCare in another way.
Our children and unborn babies are being used as commodities and soon will be traded like livestock. A California company is using organs from aborted babies to grow full sized organs for transplants. Google is on a quest for immortality. Will they turn to this sickening procedure in their quests to become gods on earth? http://www.bloomberg.com/news/articles/2015-03-09/google-ventures-bill-maris-investing-in-idea-of-living-to-500
Pharmaceutical Giant GlaxoSmithKline 'Accidentally' Released 45 Liters of Concentrated Live Polio Virus in the Environment
by Global Research News
[Belgium] As reported to ECDC by Belgian authorities, on 2 September 2014, following a human error, 45 litres of concentrated live polio virus solution were released into the environment by the pharmaceutical company, GlaxoSmithKline (GSK), in Rixensart city, Belgium. The liquid was conducted directly to a water-treatment plant (Rosieres) and released after treatment in river Lasne affluent of river Dyle which is affluent of the Escaut/Scheldt river. Belgium's High Council of Public Health conducted a risk assessment that concluded that the risk of infection for the population exposed to the contaminated water is extremely low due to the high level of dilution and the high vaccination coverage (95%) in Belgium.
ECDC's assessment is that the accidental release in the environment of large amounts of live polio virus represents a risk to public health if susceptible populations, such as areas with low polio vaccine coverage, are exposed to contaminated waters or mud. Particularly since the Lasne and Dyle rivers are joining the Escaut/Scheldt river which flows in the southwestern part of the Netherlands where various orthodox protestant communities present a lower polio vaccination coverage, before reaching the North Sea...MORE
What the Top 10 Biopharma [Obamacare] CEOs Are Making
by Alex Philippidis
These biotech leaders are the ones bringing home the most bacon:
#10. Merck & Co.
Kenneth C. Frazier, Chairman, President, and CEO
2011 Compensation: $13,347,652
2010 Compensation: $9,439,632
% Change: 41.1%
#9. Baxter International
Robert L. Parkinson Jr., Chairman and CEO
2011 Compensation: $14,065,479
2010 Compensation: $11,500,268
% Change: 22.3%
#8. Bristol-Myers Squibb
Lamberto Andreotti, CEO
2011 Compensation: $14,911,947
2010 Compensation: $11,770,880
% Change: 26.7%
#7. Gilead Sciences
John C. Martin, Chairman and CEO
2011 Compensation: $15,615,645
2010 Compensation: $14,244,388
% Change: 9.6%
Joseph Jimenez, CEO
2011 Compensation1: $15,881,621
2010 Compensation1: $11,828,828
% Change: 34.3%
#5. Eli Lilly
John C. Lechleiter, Ph.D., Chairman, President, and CEO
2011 Compensation: $16,370,094
2010 Compensation: $16,504,545
% Change: -0.8%
Kevin W. Sharer, Chairman and CEO
2011 Compensation: $18,850,311
2010 Compensation: $21,138,133
% Change: -10.8%
Miles D. White, Chairman, CEO, and Director
2011 Compensation: $24,010,902
2010 Compensation: $25,564,283
% Change: -6.1%
Ian Read, Chairman and CEO
2011 Compensation: $25,013,348
2010 Compensation: $17,396,112
% Change: 43.8%
#1. Johnson & Johnson
William C. Weldon, Chairman/CEO
2011 Compensation: $26,797,939
2010 Compensation: $28,720,491
% Change: -6.7%
1Converted to USD from CHF. [[Swiss franks]] Total compensation includes salary, bonuses if any, stock awards, option awards, non-equity incentive plan compensation, annual charge to the pension fund plus non-qualified deferred compensation earnings, and all other forms of compensation. Figures were obtained from proxy statements and annual reports.
The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.
The revelations, which marked the latest in a string of scandals at the company's Japanese subsidiary, come after local authorities slapped the firm on the wrist, saying it had to clean up its operations.
On Friday, Novartis issued a statement saying it had failed to report to regulators at least 2,579 cases where patients had suffered serious potential side effects from its drugs.
Japan's Jiji Press news agency said they included some fatal cases, without specifying a figure.
The unit declined to comment on Monday, referring questions to its Swiss headquarters.
Japanese media said the number of cases involved could rise as Novartis probes 6,000 other cases.
The news comes about four months after Novartis replaced the top executives at its Japanese arm over allegations it did not properly disclose the possible side effects of its leukaemia treatments.
In July, Japanese prosecutors laid charges against the unit over claims that falsified data was used to exaggerate the benefits of a popular blood-pressure drug.
They also indicted a former employee, Nobuo Shirahashi, alleging he manipulated the data in clinical studies that were later used in marketing the drug Valsartan.
From Cornell University Law School
Title 42 USC Â§ 18115 - Freedom not to participate in Federal health insurance programs
Current through Pub. L. 113-36. (See Public Laws for the current Congress.)
No individual, company, business, nonprofit entity, or health insurance issuer offering group or individual health insurance coverage shall be required to participate in any Federal health insurance program created under this Act (or any amendments made by this Act), or in any Federal health insurance program expanded by this Act (or any such amendments), and there shall be no penalty or fine imposed upon any such issuer for choosing not to participate in such programs.
Bayer still producing Drugs for Big Pharma even after its role in Halocaust
“Dr. Fritz ter Meer, a director of IG Farben who was directly involved in developing the nerve gas, Zyklon-B, which killed millions of Jews, was sentenced to seven years in prison but was released after four years through the intervention of Rockefeller and J.J. McCloy, then U.S. High Commissioner for Germany. An unrepentant Fritz ter Meer, guilty of genocide and crimes against humanity, returned to work in Bayer where he served as Chairman for more than 10 years, until 1961.”
Doctors and Phamacies make Millions selling Chemotherapy and drugs. Chemotherapy fails 97% of the time. There is NO research into alternative treatments
Finally it’s coming to light and the fact is being told: Vaccines given to infants contained inordinate amounts of ethylmercury in…
Hidden Clinical Trial Data about Lupron
Merck vaccine fraud exposed by two Merck virologists. Merck used falsified trial results to swindle the U.S. government out of hundreds of millions of dollars for a mumps vaccine that does not provide adequate immunization: http://www.naturalnews.com/gallery/documents/Merck-False-Claims-Act.pdf
Health Care Drug Plans
A graduate student at the University of Colorado Denver faked data in his work at a drug research lab that has notched two retractions and an expression of concern over data integrity, according to an extensive university investigation. It seems like many more retractions are on the horizon for grad student Rajendra Kadam, who worked in the lab of Uday Kompella, a pharmaceutical researcher at the university. Here's an excerpt from the report, which you can read in full (but redacted) here: Read the rest of this entry
Seventh retraction appears for author who tampered with investigation
Here's the notice for 'Carboxylated calixarenes bind strongly to CD69 and protect CD69+killer cells from suicidal cell death induced by tumor cell surface ligands, which was first published in Bioorganics & Medicinal Chemistry in 2010: Read the rest of this entry at:
Want bogus data, million-dollar fraud allegations and a scientist on the lam? We give you Alain Malafosse. The British Journal of Psychiatry has retracted a June 2013 paper by Malafosse and his colleagues on the genetics of bipolar disorder in children because Malafosse allegedly fabricated key data in the study. The article, Childhood maltreatment and methylation of the glucocorticoid receptor gene NR3C1 in bipolar disorder, purported to find that people with bipolar disorder who had experienced more, and more severe, abuse early in life were more likely to show epigenetic changes. According to the abstract: Read the rest of this entry